Showing 1 - 10 of 241
This paper analyzes the timing decisions of pharmaceutical firms to launch a new drug in countries involved in international reference pricing. We show three important features of launch timing when all countries reference the prices in all other countries and in all previous periods of time....
Persistent link: https://www.econbiz.de/10010826795
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a firm commercializes a new drug is larger when countries do not approve...
Persistent link: https://www.econbiz.de/10010936719
We develop a theoretical model to compare the two major foreign aid modalities: project aid and budget support. These two modalities have a different impact on the production of ‘developmental goods’. Firstly, conditionality can be associated with budget support, but only a subset of the...
Persistent link: https://www.econbiz.de/10005056878
Persistent link: https://www.econbiz.de/10005520129
Conditionality, and the extent to which it should be associated with development aid, has been a major concern within the donor community over the past decades. Practitioners argue in favour of associating budget support (BS) with some level of conditionality. A scientific analysis by Cordella...
Persistent link: https://www.econbiz.de/10011095699
In this paper, we give a new insight on the relationship between the patients' co-payment for buying pharmaceuticals and the price of a patented pharmaceutical. We consider that the price of a pharmaceutical is the outcome of a negotiation between a health authority and a pharmaceutical monopoly...
Persistent link: https://www.econbiz.de/10011199671
Some countries allow physicians to balance bill patients, that is, to bill a fee above the one that is negotiated with, and reimbursed by the health authorities. Balance billing is known for restricting access to physicians' services while supplemental insurance against balance billing amounts...
Persistent link: https://www.econbiz.de/10010821174
This paper analyzes the timing decisions of pharmaceutical firms to launch a new drug in countries involved in international reference pricing. We show three important features of launch timing when all countries reference the prices in all other countries and in all previous periods of time....
Persistent link: https://www.econbiz.de/10010899619
This paper analyzes the consequences of allowing gatekeeping general practitioners (GPs) to select their payment mechanism. We model GPs’ behavior under the most common payment schemes (capitation and fee for service) and when GPs can select one among them. Our analysis considers GP...
Persistent link: https://www.econbiz.de/10010863343
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a firm commercializes a new drug is larger when countries do not approve...
Persistent link: https://www.econbiz.de/10010935046